Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021

JAMA Netw Open. 2021 Dec 1;4(12):e2138975. doi: 10.1001/jamanetworkopen.2021.38975.

Abstract

This case-control study examines estimated COVID-19 messenger RNA vaccination effectiveness against SARS-CoV-2 infection from January to September 2021 among fully vaccinated male veterans aged 65 years or older.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Aged
  • Aged, 80 and over
  • BNT162 Vaccine
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines*
  • Humans
  • Male
  • RNA, Messenger*
  • SARS-CoV-2
  • Treatment Outcome
  • United States
  • United States Department of Veterans Affairs
  • Vaccination*
  • Veterans Health Services
  • Veterans Health*
  • Veterans*

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine

Supplementary concepts

  • SARS-CoV-2 variants